Basic Information
LncRNA/CircRNA Name | CASC2 |
Synonyms | CASC2, C10orf5 |
Region | GRCh38_10:118046279-118210153 |
Ensemble | ENSG00000177640 |
Refseq | NR_026939 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | glioma |
ICD-0-3 | NA |
Methods | qPCR, RNAi, Western blot, RIP, Luciferase reporter assay, MTT assay etc. |
Sample | glioma tissues, cell lines (U251, U373, SNB19, U118, and LN229) |
Expression Pattern | down-regulated |
Function Description | CASC2 expression was down-regulated in glioma tissues and cell lines. Exogenous CACS2 alone was sufficient to inhibit glioma cells' proliferation and amplified TMZ-induced repression of cell proliferation, while CACS2 knockdown could reverse this process. CASC2 up-regulates PTEN through direct inhibiting miR-181a and plays an important role in glioma sensitivity to TMZ and may serve as a potential target for cancer diagnosis and treatment. |
Pubmed ID | 28121023 |
Year | 2017 |
Title | LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. |
External Links
Links for CASC2 | GenBank HGNC NONCODE |
Links for glioma | OMIM COSMIC |